Advertisement

Antidepressants and traffic safety

  • Joris C. Verster
  • Johannes G. Ramaekers

Abstract

Depression is a common disease that is often pharmaceutically treated with tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). Both groups of drugs have proven to be effective in treating depressive symptoms, however they differ in adverse effect profile. This chapter discusses their effects on driving ability. On the road driving tests have shown that TCAs such as imipramine, doxepine and amitriptilyne significantly impair driving performance after single dose administration. However, after one to two weeks of daily treatment tolerance developed and no significant driving impairment was reported. Sedative antidepressants such as mianserin and mitrazapine administered at bedtime produce significant driving impairment the morning following single dose administration and after one week of daily treatment. In contrast, SSRIs such as fluoxetine and paroxetine had no significant effects on driving ability. Also, venlafaxine did not affect driving performance. The chapter concludes by discussing that untreated depression impairs driving ability and that reported somnolence correlates significantly with reduced driving performance.

Keywords

Single Dose Administration KDYH EHHQ WKDQ WKDW 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Louwerens JW, Brookhuis KA, O’Hanlon JF (1984) The effects of antidepressants oxaprotiline, mianserin, amitriptyline and doxepin upon actual driving performance. Groningen, The Netherlands. Traffic research Center, technical report.Google Scholar
  2. 2.
    Schoenmakers EAJM, Robbe HWJ, O’Hanlon JF (1989) Acute and subchronic effects of the antidepressants levoprotiline and doxepin on the performance of healthy volunteers in psychometric and actual driving tests. Maastricht, The Netherlands. University of Maastricht, Institute for Human Psychopharmacology, technical report.Google Scholar
  3. 3.
    Ramaekers JG, van Veggel LM, O’Hanlon JF (1994) A cross-study comparison of the effects of moclobemide and brofaromide on actual driving performance and estimated sleep. Clin Neuropsychopharmacol 17(suppl 1): S9–S18.Google Scholar
  4. 4.
    Robbe HW, O’Hanlon JF (1995) Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. Eur Neuropsychopharmacol 5: 35–42.PubMedCrossRefGoogle Scholar
  5. 5.
    van Laar MW, van Willigenburg AP, Volkerts ER (1995) Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 15: 30–40.PubMedCrossRefGoogle Scholar
  6. 6.
    Ramaekers JG, Swijgman HF, O’Hanlon JF (1992) Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo. Psychopharmacology 106 (suppl): S62–S67.PubMedCrossRefGoogle Scholar
  7. 7.
    O’Hanlon JF, Robbe HW, Vermeeren A et al. (1998) Venlafaxine’s effects on healthy volunteers’ driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. J Clin Psychopharmacol 18: 212–221.PubMedCrossRefGoogle Scholar
  8. 8.
    Ramaekers JG, Muntjewerff ND, O’Hanlon JF (1995) A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol 39: 397–404.PubMedGoogle Scholar
  9. 9.
    Ramaekers JG, Muntjewerff ND, van Veggel LMA et al. (1998) Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance in young, healthy volunteers. Hum Psychopharmacol Clin Exp 13(suppl 2): S7–S97.Google Scholar
  10. 10.
    Wingen M, Bothmer J, Langer S, Ramaekers JG (2005) Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 66: 436–443.PubMedGoogle Scholar
  11. 11.
    Ramaekers JG. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. J Clin Psychiatry 2003, 64: 20–29.PubMedCrossRefGoogle Scholar
  12. 12.
    Wingen M, ramaekers JG, Schmitt AJ (2006) driving impairment in depressed patients receiving long-term antidepressant treatment. Psychopharmacology 188: 84–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Leveille SG, Buchner DM, Koepsell TD, McCloskey LW, Wolf ME, Wagner EH (1994) Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology 5: 591–598PubMedCrossRefGoogle Scholar
  14. 14.
    Ray WA, Fought RL, Decker MD (1992) Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 136: 873–883PubMedCrossRefGoogle Scholar
  15. 15.
    Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG, MacDonald TM (1998) Association of road-traffic accidents with benzodiazepine use. Lancet 352: 1331–1336PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2009

Authors and Affiliations

  • Joris C. Verster
    • 1
  • Johannes G. Ramaekers
    • 2
  1. 1.Utrecht University, Faculty of ScienceSection PsychopharmacologyUtrechtThe Netherlands
  2. 2.Department of Neuropsychology and Psychopharmacology, Faculty of PsychologyMaastricht UniversityThe Netherlands

Personalised recommendations